{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    8,
    13,
    30,
    42,
    57
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Schedule of Activities Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference to the Schedule of Activities for study procedures"
      },
      {
        "id": "ref_2",
        "name": "COVID-19 Procedures Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 8",
        "sectionTitle": "Changes to Study Procedures due to the COVID-19 Pandemic",
        "description": "Reference for instructions regarding patients affected by SARS-CoV-2"
      },
      {
        "id": "ref_3",
        "name": "Concomitant Therapy Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.7",
        "sectionTitle": "Concomitant Therapy",
        "description": "Reference for prohibited medications including GLP-1 receptor agonists and DPP-4 inhibitors"
      },
      {
        "id": "ref_4",
        "name": "Pharmacokinetics Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.5",
        "sectionTitle": "Pharmacokinetics",
        "description": "Reference for PK sample collection details"
      },
      {
        "id": "ref_5",
        "name": "Hyperglycemia Thresholds Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.2.1.2 and 9.2.2.2",
        "sectionTitle": "Insulin Glargine / Severe, Persistent Hyperglycemia",
        "description": "Reference for prespecified thresholds for rescue therapy"
      },
      {
        "id": "ref_6",
        "name": "Study Governance Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 3",
        "sectionTitle": "Study Governance Considerations",
        "description": "Reference for detailed study governance considerations"
      },
      {
        "id": "ref_7",
        "name": "Hypoglycemia Management Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.2.2.1",
        "sectionTitle": "Hypoglycemia",
        "description": "Reference for further information on managing hypoglycemic episodes"
      },
      {
        "id": "ref_8",
        "name": "Hepatic Monitoring Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.4.5.1 and Appendix 4",
        "sectionTitle": "Hepatic Safety Monitoring / Hepatic Monitoring Tests",
        "description": "Reference for hepatic monitoring in cases of elevated liver markers"
      },
      {
        "id": "ref_9",
        "name": "GI AE Management Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.7.1",
        "sectionTitle": "Management of Patients with Gastrointestinal Symptoms",
        "description": "Reference for detailed information concerning the management of GI Adverse Events"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "This document may contain protected personal data and/or commercially confidential information exempt from public disclosure.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Confidential Information",
        "pageNumber": 2
      },
      {
        "id": "annot_2",
        "text": "In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Confidential Information",
        "pageNumber": 2
      },
      {
        "id": "annot_3",
        "text": "Initiation of new antihyperglycemic therapy for the safety follow-up period will not be classified as rescue therapy.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Study Period IV (safety follow-up period)",
        "pageNumber": 31
      },
      {
        "id": "annot_4",
        "text": "56 mg/dL threshold for sulfonylurea dosage reduction/discontinuation.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "7.4.2",
        "pageNumber": 43
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "Original",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2018-07-18",
        "description": "Protocol Electronically Signed and Approved by Lilly",
        "amendmentNumber": "N/A"
      },
      {
        "id": "ver_2",
        "versionNumber": "Amendment (a)",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2018-09-28",
        "description": "Amendment (a) Electronically Signed and Approved",
        "amendmentNumber": "a"
      },
      {
        "id": "ver_3",
        "versionNumber": "Amendment (b)",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-07-10",
        "description": "Protocol Amendment I8F-MC-GPGM(b) incorporating changes",
        "amendmentNumber": "b"
      }
    ],
    "summary": {
      "referenceCount": 9,
      "annotationCount": 4,
      "versionCount": 3
    }
  }
}